Why one in three prescriptions is never filled — and where pharma can actually intervene

A prescription written is not a prescription filled. Roughly one in three new prescriptions is never picked up from the pharmacy, and around one in two patients on chronic therapy stops taking it within twelve months.

These are among the most quoted numbers in pharmaceutical commercial teams and among the least acted upon - not because brands don't care, but because the moment where abandonment happens has sat outside the reach of any media channel.

Abandonment is a distribution problem, not a behaviour problem

Prescription abandonment is usually framed as patient behaviour, which quietly implies the solution is education. That framing misses where and why it actually happens.

The majority of first-fill abandonment occurs at one place - the pharmacy counter - at one moment: when the patient learns what the medication will cost them. The common triggers are narrow and specific:

• Cost shock. The copay is materially higher than expected and the patient walks away.
• Prior authorization. The script can't be filled today, requires paperwork nobody has started, and the patient doesn't return.
• Coverage rejection. The claim doesn't adjudicate as expected and there is no obvious next step at the counter.
• Deductible timing. The same script that was affordable in November isn't in January.

What unites these is that none of them are knowable when the prescription is written. The physician doesn't see the patient's real out-of-pocket cost at the point of prescribing. The patient doesn't learn it until adjudication. By then the physician is three patients further into their day.

The information that would prevent the abandonment already exists. It just arrives at a counter, in a workflow nobody has been standing in. 

Why patient-directed messaging under-performs here

The standard industry response is a patient support program - a copay card, a hub, an affordability portal. These programs are frequently excellent and frequently under-used.

That gap is a distribution failure rather than a design failure. A copay card only works if the patient knows it exists at the moment cost becomes the obstacle. Reaching that patient by email three days later, or by display advertising a week later, is reaching them after the decision has already been made - and a significant share of patients who abandon never re-present at all.

The window is minutes wide. It occurs inside a transaction the brand cannot see. And the only person present for it is the pharmacist.

The four points of intervention, ranked by leverage 

There are really only four places a brand can act on abandonment, and they are not equally powerful.

⁠1 · Before the visit. Priming the patient in the clinical environment so they arrive informed. Useful, indirect, and hard to attribute.

2 · At prescribing. Giving the physician visibility into access pathways at the moment they choose. High leverage, but the physician still doesn't see the patient's actual out-of-pocket cost.

3 · In the patient portal after the visit. Reaching the patient where they read results, pay, and schedule refills. Closer to the decision, and consent-gated.

4 · At the counter, during adjudication. The only point where the real cost is known, the patient is physically present, and someone with clinical authority is standing in front of them. Highest leverage by a distance - and historically unreachable.

What a credible point-of-dispense intervention requires 

Three constraints separate a serious approach from a careless one.

It has to be in workflow. A message the pharmacist must go and look for is not an intervention. It has to appear in the pharmacy management system they are already working in, on the specific script they are already processing.

It has to be triggered on the live event. Not a daily file, not a modelled likelihood - the live NDC, at adjudication, for that patient's specific claim.

It has to suppress correctly. Manufacturer copay assistance cannot be applied to Medicare Part D, Medicaid, or other federal healthcare program beneficiaries. Any affordability message firing at adjudication must suppress on federal claims. This is a hard technical requirement, not a disclaimer, and it is a fair question to put to any vendor offering the capability.

How to measure it honestly 

Abandonment work should be measured on abandonment. The metrics that matter:

• First-fill rate - what share of written scripts are picked up
• Time to first fill - how long between written and filled
• Support program utilization - how many eligible patients actually use the help that exists
• Persistence at 6 and 12 months - whether the refill sequence holds

All four should be read against a matched control. An uncontrolled read on abandonment is not evidence: abandonment rates move seasonally, with deductible cycles, and with formulary changes that have nothing to do with any media program. If a vendor shows a lift number and can't describe the control design, the number isn't telling you what you think it is.

Why this is the largest unaddressed leak in most brands' funnels

For most chronic and specialty brands, the gap between prescriptions written and prescriptions filled is larger than most share-shift opportunities, already quantified in internal reporting, and sitting downstream of every dollar already spent on prescriber promotion.

A brand that improves first-fill rate is not acquiring new demand. It is collecting demand it already created and already paid for.

Doceree reaches pharmacists inside the pharmacy management system, triggered on the live NDC at script processing, across 40,000+ US pharmacies - as part of a connected sequence spanning all seven moments of a clinical encounter.